Kuo-Wei Bi

Kuo-Wei Bi

Auto-generated profile, based on publicly available information

Kuo-Wei Bi

Division of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
CYChih-Chien Yao
Chih-Chien Yao
CKChung-Mou Kuo
Chung-Mou Kuo
CHChien-Ning Hsu
Chien-Ning Hsu
SYShig-Cheng Yang
Shig-Cheng Yang
CWCheng-Kun Wu
Cheng-Kun Wu
SCSeng-Kee Chuah
Seng-Kee Chuah
Purpose: To assess the difference of the first-line therapy for Helicobacter pylori in patients with or without type 2 diabetes (DM) and to investigate the clinical factors influencing treatment outcomes. Patients and methods: In total, 719 patients with H. pylori infection were treated with 7-day standard first-line triple therapy, of whom 182 did and 537 did not have DM. Propensity score matched at a 1:2 ratio – for age, sex and body mass index was performed for the two groups, yielding a DM group with 147 patients and a non-DM group with 249 matched controls for analysis. Urea breath test was performed 6–8 weeks after treatment. Clinical and laboratory parameters were collected for identifying factors associated with failed eradication. Results: H. Pylori was eradicated in 74.1% (95% confidence interval [CI] =66.2–81.0) of the DM group and 85.3% (95% CI =80.8–89.4) of the non-DM group (p=0.005). Of 51 gastric biopsy samples cultured for H. pylori, 41 were positive. In the DM group, the rates of resistance to amoxicillin, clarithromycin, levofloxacin, and tetracycline were 0%, 50.0%, 50.0% and 0%, respectively. In the non-DM group, the comparable proportions were 2.9%, 17.1%, 22.9%, and 0%, respectively. Univariate analysis revealed that DM (Odds ratio [OR], 1.771, 95% CI, 1.167–2.668, p=0.006), clarithromycin resistance (OR, 15.273; 95% CI, 1.687–138.269; p=0.015), and amoxicillin resistance (OR, 4.672; 95% CI, 2.431–8.979; p90% eradication.

1 September 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
WTWei-Chen Tai
Wei-Chen Tai
CLChih-Ming Liang
Chih-Ming Liang
KBKuo-Wei Bi
Kuo-Wei Bi
CKChung-Mou Kuo
Chung-Mou Kuo
LLLung-Sheng Lu
Lung-Sheng Lu
SCSeng-Kee Chuah
Seng-Kee Chuah
Purpose: Steadily maintaining high intra-gastric PH is the major factor for successful Helicobacter pylori (H.pylori) eradication. It is important to search for a stronger PPI. Dexlansoprazole MR is a dual delayed release formulation PPI taken once daily which is capable of maintaining longer duration of high intra-gastric PH. It is very effective in treating gastroesophageal disease but reports on H, pylori eradication is very rare. This study sought to compare dexlansoprazole MR-based concomitant treatment and lansoprazole-based concomitant treatment in H. pylori infection and to investigate the factors that affect the eradication rates. Methods: Two hundred two participants with H. pylori infection were included and randomly assigned to seven days of dexlansoprazole MR-based concomitant therapy (dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily; DACM group) or a seven days of lansoprazole-based concomitant therapy (lansoprazole 30 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, and metronidazole 500 mg twice daily; LACM group). The participants were asked to perform urea breath tests eight weeks later. Results: The eradication rates in the DACM group were 86.1% [95% confidence interval (CI): 77.8%–92.2%] in the ITT analysis and 90.6% (95% CI: 82.9%–95.6%) in the PP analysis, respectively, as compared with 90.1% (95% CI: 82.6%–95.2%) and 92.6% (95% CI: 85.5%–96.9%) (p=0.384 and p=0.572, respectively) in the LACM group for the same analyses. The adverse event rates were 11.5% in the DACM group and 10.2% in the LACM group (p=0.779). Conclusion: As a first-line H. pylori treatment regimen, dexlansoprazole MR-based concomitant therapy attained a successful eradication rate of 90%, which was non inferior to that of lansoprazole-based concomitant treatment. ClinicalTrials.gov identifier: NCT03829150.

1 September 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
WTWei-Chen Tai
Wei-Chen Tai
CLChih-Ming Liang
Chih-Ming Liang
KBKuo-Wei Bi
Kuo-Wei Bi
CKChung-Mou Kuo
Chung-Mou Kuo
LLLung-Sheng Lu
Lung-Sheng Lu
SCSeng-Kee Chuah
Seng-Kee Chuah
A Comparison Between Dexlansoprazole Modified Release-Based And Lansoprazole-Based Nonbismuth Quadruple (Concomitant) Therapy For First-Line Helicobacter pylori Eradication: A Prospective Randomized Trial [Corrigendum] Tai WC, Liang CM, Bi KW, et al. Infect Drug Resist. 2019;12:2923–2931.Following a review of our paper post-publication, we found under the ethics approval and informed consent section on page 2929, the IRB number is incorrect. The correct statement is “This study’s protocol was approved by the institutional review board and the ethics committee of Chang Gung Memorial Hospital (IRB 201601061A3)”. The authors apologize for this error.Read the original article